长春高新：长春百克生物科技股份公司收到《药物临床试验批准通知书》

Group 1 - The core point of the article is that Changchun High-tech has received approval from the National Medical Products Administration for its trivalent influenza virus split vaccine, indicating a significant advancement in its pharmaceutical development [1] - As of October 13, Changchun High-tech's market capitalization is 53.9 billion yuan [2] - The revenue composition for Changchun High-tech in the first half of 2025 shows that the pharmaceutical sector accounts for 92.83%, real estate for 6.81%, and services for 0.36% [1]